CompoAtlas

EU YAN SANG PROSTA MEN CAPSULES

EU YAN SANG PROSTA MEN CAPSULES : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
Vaccinium macrocarponVaccinium macrocarpon[30 mg,500 mg]Not identified
Serenoa repensSerenoa repens[160 mg,500 mg]Not identified
Amomum villosumAmomum villosum[20 mg,500 mg]Not identified
Dioscorea hypoglaucaDioscorea hypoglauca[20 mg,500 mg]Not identified
Liquidambar formosanaLiquidambar formosana[20 mg,500 mg]Not identified
Secale cerealeSecale cereale[250 mg,500 mg]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
MAL23036110T
Type
Natural product
Published status
PRODUCT APPROVED
Licence holder
WENG LI SDN. BHD.
Manufacturer
WENG LI SDN. BHD.
Registration period starting
2023-03-21
Published validity end
2028-03-21

Original register data

View published fields and their variants
Active ingredients
Vaccinium macrocarpon[30 mg,500 mg],Serenoa repens[160 mg,500 mg],Amomum villosum[20 mg,500 mg],Dioscorea hypoglauca[20 mg,500 mg],Liquidambar formosana[20 mg,500 mg],Secale cereale[250 mg,500 mg]
Valid until
2028-03-21
Registration date
2023-03-21
Published description
NATURAL PRODUCT
Licence holder
WENG LI SDN. BHD.
Producer
WENG LI SDN. BHD.
Published name
EU YAN SANG PROSTA MEN CAPSULES
Published reference
202210059053T
Registration number
MAL23036110T
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL23036110T

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium macrocarpon
    Read the warning, when it applies and the studies cited

    CRANBERRY - VACCINIUM MACROCARPON

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    DRIED CRANBERRY JUICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

  • Serenoa repens
    Read the warning, when it applies and the studies cited

    SAW PALMETTO – SERENOA REPENS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All subpopulations.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Adult males only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.

    Condition of application: Adult females only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).

    Sources cited by Health Canada (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Contraindications

    Condition of application: Adult females only.

    Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).

    Sources cited by Health Canada (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “EU YAN SANG PROSTA MEN CAPSULES”, https://compoatlas.com/en/supplements/malaysia/MAL23036110T-eu-yan-sang-prosta-men-capsules, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line